Author: Marty, Francisco M; Chemaly, Roy F; Mullane, Kathleen M; Lee, Dong-Gun; Hirsch, Hans H; Small, Catherine B; Bergeron, Anne; Shoham, Shmuel; Ljungman, Per; Waghmare, Alpana; Blanchard, Elodie; Kim, Yae-Jean; McKevitt, Matt; Porter, Danielle P; Jordan, Robert; Guo, Ying; German, Polina; Boeckh, Michael; Watkins, Timothy R; Chien, Jason W; Dadwal, Sanjeet S
Title: A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract Document date: 2019_12_3
ID: sl45z4i0_10
Snippet: Patients received presatovir 200 mg (4 × 50 mg tablets) or placebo orally or via nasogastric tube every 4 days (±24 hours) during study visits on days 1, 5, 9, 13, and 17, and were followed through study day 28. Patients RSV-positive by local molecular testing on day 22 could participate in an optional extended weekly follow-up through day 56. A detailed schedule of study assessments and procedures is provided in Supplemental Table 1 ......
Document: Patients received presatovir 200 mg (4 × 50 mg tablets) or placebo orally or via nasogastric tube every 4 days (±24 hours) during study visits on days 1, 5, 9, 13, and 17, and were followed through study day 28. Patients RSV-positive by local molecular testing on day 22 could participate in an optional extended weekly follow-up through day 56. A detailed schedule of study assessments and procedures is provided in Supplemental Table 1 .
Search related documents:
Co phrase search for related documents- mg tablet and nasogastric tube: 1
- mg tablet and study day: 1, 2, 3, 4, 5
- molecular testing and study assessment: 1, 2
- molecular testing and study day: 1
- nasogastric tube and study day: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date